Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8104876 | 0.85 | KEAP1 (0.40) | HRH3SCN5ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL8095289 | 0.77 | CARM1 (0.36) | HRH3ACE2ALDH1A1TSHRKDM1A | |
| SCHEMBL8104652 | 0.76 | TDP1 (0.41) | — | |
| SCHEMBL9375717 | 0.75 | ACE2 (0.37) | ACE2SMN1; SMN2KDM1A | |
| SCHEMBL8104864 | 0.72 | TDP1 (0.37) | — | |
| SCHEMBL18568453 | 0.71 | HRH3 (0.52) | HRH3SCN5ASMN1; SMN2LMNAMAPT | |
| SCHEMBL8307200 | 0.71 | ACE2 (0.61) | HRH3SCN5AACE2SMN1; SMN2ALDH1A1 | |
| SCHEMBL12309176 | 0.71 | HRH3 (0.52) | HRH3SCN5ASMN1; SMN2LMNAMAPT | |
| SCHEMBL8104892 | 0.71 | HSD17B10 (0.44) | ACE2SMN1; SMN2ALDH1A1TSHRKDM1A | |
| SCHEMBL8095419 | 0.71 | KEAP1 (0.33) | SMN1; SMN2ALDH1A1TSHRKDM1ACARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | BRAF, NRAS, RAF1 | HRH3 1308/4885SCN5A 1468/4885ACE2 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.